| Document And Entity Information | Aug. 23, 2023 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Document Period End Date | Aug. 23, 2023 |
| Entity Registrant Name | Pyxis Oncology, Inc. |
| Entity Central Index Key | 0001782223 |
| Entity Emerging Growth Company | true |
| Securities Act File Number | 001-40881 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 83-1160910 |
| Entity Address, Address Line One | 321 Harrison Avenue |
| Entity Address, City or Town | Boston |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02118 |
| City Area Code | 617- |
| Local Phone Number | 221-9059 |
| Entity Information, Former Legal or Registered Name | |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | true |
| Title of 12(b) Security | Common Stock, par value $0.001 per share |
| Trading Symbol | PYXS |
| Security Exchange Name | NASDAQ |
| Amendment Description | This Current Report on Form 8-K/A (the "Amendment") amends the Current Report on Form 8-K (the "Original 8-K") filed by Pyxis Oncology, Inc. (the "Company") with the Securities and Exchange Commission (the "SEC") on August 23, 2023 reporting that the Company completed its acquisition of Apexigen, Inc. ("Apexigen") on August 23, 2023. The Company is filing this Amendment solely to amend and supplement the Original 8-K to provide certain financial information required by Item 9.01 of Form 8-K, which the Company is permitted to file by amendment no later than 71 days after the due date of the Original 8-K. Except as set forth herein, no other amendments to the Original 8-K are being made by this Amendment. |
